Intech Investment Management LLC Cuts Stock Holdings in Boston Scientific Corporation $BSX

Intech Investment Management LLC reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 45.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,245 shares of the medical equipment provider’s stock after selling 147,689 shares during the quarter. Intech Investment Management LLC’s holdings in Boston Scientific were worth $16,805,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Foundations Investment Advisors LLC increased its holdings in shares of Boston Scientific by 4.5% in the 4th quarter. Foundations Investment Advisors LLC now owns 5,192 shares of the medical equipment provider’s stock worth $495,000 after buying an additional 225 shares during the last quarter. Baker Avenue Asset Management LP grew its position in Boston Scientific by 4.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 27,821 shares of the medical equipment provider’s stock worth $2,653,000 after acquiring an additional 1,190 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in Boston Scientific in the fourth quarter valued at $322,000. IFG Advisory LLC raised its position in Boston Scientific by 177.7% during the fourth quarter. IFG Advisory LLC now owns 16,966 shares of the medical equipment provider’s stock valued at $1,618,000 after purchasing an additional 10,856 shares in the last quarter. Finally, Thoroughbred Financial Services LLC lifted its stake in Boston Scientific by 340.6% during the fourth quarter. Thoroughbred Financial Services LLC now owns 10,694 shares of the medical equipment provider’s stock worth $1,019,000 after purchasing an additional 8,267 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Insider Buying and Selling

In related news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 2.7%

NYSE BSX opened at $49.12 on Friday. The firm has a market capitalization of $73.01 billion, a PE ratio of 20.55, a P/E/G ratio of 0.93 and a beta of 0.62. The stock’s 50 day moving average is $60.69 and its 200 day moving average is $78.84. Boston Scientific Corporation has a twelve month low of $48.41 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BSX. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. TD Cowen cut their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.46.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.